NEW YORK – Oxford Nanopore Technologies said on Monday that it has inked a research collaboration agreement with the Norwegian Centre for Clinical Cancer Research, dubbed Matrix, to explore the clinical utility of nanopore sequencing in precision cancer medicine.
Financial details of the deal were not disclosed.
Under the partnership, Oxford Nanopore and Matrix will focus on central nervous system (CNS) tumors and will develop single-cell methods for analyzing DNA methylation, somatic and pathogenic copy number variants, tumor heterogeneity of gene expression, and mutations and fusions.
The research collaboration will use Oxford Nanopore's PromethIon 24 device and will be conducted at Oslo University Hospital, under the direction of professor Hege Russnes, who leads InPreD, Norway's national precision diagnostics in cancer program, the company said.